Epilepsy in Glioblastoma Patients: Etiopathogenesis and Treatment
DOI:
https://doi.org/10.61788/njn.v2i26.14Keywords:
glioblastoma, epileptic seizure, antiepileptic drugsAbstract
Patients with glioblastoma (GB) experience seizures as a complex clinical problem caused by tumor-related changes in brain structure, neurochemical processes, and electrical activity. Managing seizures in these patients requires a comprehensive approach, including careful selection of antiepileptic drugs, surgical interventions when necessary, and consideration of additional therapies such as radiation therapy and chemotherapy. Despite progress in understanding the mechanisms underlying seizures in GB, much remains to be done in developing targeted and immunotherapy approaches that could provide more effective and personalized treatment options. The growing body of research into the molecular and cellular mechanisms of epileptogenesis in GB offers hope for the development of new therapeutic strategies that could improve both seizure control and overall treatment outcomes for patients.
References
Huang R.Y., Neagu M.R., Reardon D.A., Wen P.Y. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response // Frontiers in Neurology, 2015, v. 6, p.33. doi: 10.3389/fneur.2015.00033
Mendez J.C., Mukherjee D. Mechanisms of epilepsy in gliomas // Frontiers in Neurology, 2019, No 10, pp. 119.
Falko L., Julia H., Timo K. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy // Cells., 2021, No 10(5), pp. 1226. doi: 10.3390/cells10051226
Pires S.M., Nascimento M.F. Inflammation and seizure mechanisms in glioma // Frontiers in Neuroscience, 2017, No 11,pp. 321.
Liu,X., Zhang J. Blood-brain barrier disruption in gliomas: Mechanisms and clinical applications // Frontiers in Neuroscience, 2015, No 9, pp. 256.
Vecht C.J., Wagner G.L., Wilms E.B. Interactions between antiepileptic and chemotherapeutic drugs // The Lancet Neurology, 2003, No 2(7) pp. 404-409. doi: 10.1016/S1474-4422(03)00435-6
Mayer M., Bader, S. Impact of cognitive decline on the treatment of glioblastoma // Journal of Clinical Oncology, 2019, No 37(12), pp. 1027-1035.
Terri S.A., Robin G., Marc R G., Jong W.L., Andrew D.N. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy // Journal of Neuro Oncology, 2015, No 18(6), pp. 779-789. doi: 10.1093/neuonc/nov269
Weller M., Gorlia T., Cairncross J.G., Mason W., Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma // Neurology Journals, 2011, No 77 (12), pp. 1156-1164. doi: 10.1212/WNL.0b013e31822f02e1
Strauss I, Gabay S, Roth J. Laser interstitial thermal therapy (LITT) for pediatric low-grade glioma—case presentations and lessons learned // Childs Nerv Syst., 2024, No 40 (10), pp. 3119-3127. doi:10.1007/s00381-024-06419-3
Thomas J.G., Rao G., Kew Y., Prabhu S.S. Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma // Neurosurgical Focus, 2016, No 41 (4), pp. E12. doi: 10.3171/2016.7.FOCUS16234
Sotgiu S., Zajac J. Targeted therapies for glioma-associated epilepsy // Journal of Clinical Neuroscience, 2018, No 47, pp. 45-49.
Reardon D.A., Wen P.Y. Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents // The Oncologist, 2006, No 11(2), pp. 152-164. doi: 10.1634/theoncologist.11-2-152
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
